LivaNova PLC: Transaction In Own Shares
15 November 2016
TRANSACTION IN OWN SHARES
LivaNova PLC (the “Company” or “LivaNova”) announces that on 15 November 2016, the Board of Directors of LivaNova PLC (“LivaNova” or the “Company”) approved an amendment (the “Amended Share Repurchase Programme”) to the share repurchase programme previously approved by the Board of Directors on 1 August 2016 (the “Share Repurchase Programme”). The Share Repurchase Programme had authorised the Company to repurchase up to $30 million of the Company’s ordinary shares from 1 September 2016 through 31 December 2016 (with further repurchases in each of 2017 and 2018.) The Amended Share Repurchase Programme authorises the Company to repurchase up to $50 million of the Company’s ordinary shares through 31 December 2016 (instead of the originally authorised $30 million.) The Amended Share Repurchase Programme is in accordance with an authority approved by the Company’s shareholders at its annual general meeting on 15 June 2016. Purchases of the ordinary shares under the Amended Share Repurchase Programme will be carried out on NASDAQ and will be notified to the market through a UK Regulatory Information Service on the business day following the calendar day on which the repurchase occurred. Ordinary shares repurchased by the Company through the Amended Share Repurchase Programme will be cancelled. Until further notice, the Amended Share Repurchase Programme will be conducted pursuant to Rule 10b5-1 under the U.S. Securities Exchange Act and may therefore continue during closed periods in accordance with applicable restrictions.
LivaNova PLC is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,600 employees worldwide and is headquartered in London, U.K. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Surgery, Cardiac Rhythm Management, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
For more information, please visit www.livanova.com, or contact:
Investor Relations and Media
Vice President, Investor Relations & Corporate Communications
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332